"We are delighted to forge this exciting alliance with Ventana as we solidify our ongoing commitment to the digital pathology market," comments Mike Sklar, Vice President Sales, Healthcare for Barco North America. "Ventana offers all the ingredients for a successful partnership: in-depth market knowledge, a passion for technology excellence, and unwavering dedication to customer needs - all of the tenets that Barco upholds, which have cemented our industry leadership in healthcare imaging."

Ventana launched the newly integrated solution in North America, Asia, Europe, Latin America, the Middle East and Africa on June 3, 2013.


About Ventana Medical Systems, Inc.
http://ventana.com/ ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

VENTANA, the VENTANA logo, iScan, and VIRTUOSO are trademarks of Roche.

Visit www.ventana.com to learn more.

About Barco
Barco, a global technology company, designs and develops visualization products for a variety of selected professional markets. Barco has its own facilities for Sales & Marketing, Customer Support, R&D and Manufacturing in Europe, North America and Asia Pacific. Barco (NYSE Euronext Brussels: BAR) is active in more than 90 countries with about 3,900 employees worldwide. Barco posted sales of 1.156 billion euro in 2012.

Back to HCB News

More HCB News